Journal article
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: Results of a phase II study
A Younes, A Sureda, D Ben-Yehuda, PL Zinzani, TC Ong, HM Prince, SJ Harrison, M Kirschbaum, P Johnston, J Gallagher, C Le Corre, A Shen, A Engert
Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2012
Abstract
Purpose: Hodgkin's lymphoma (HL) has no standard of care for patients who are relapsed or refractory to autologous stem-cell transplantation (ASCT). This phase II study examined safety and activity of panobinostat in this population. Patients and Methods: Panobinostat 40 mg was administered orally three times per week. The primary end point was objective response rate (ORR) based on investigator assessment of radiologic imaging. Secondary end points included ORR by independent central review, time to response (TTR), duration of response (DOR), progression-free survival (PFS), overall survival, and safety. Exploratory biomarker analyses were performed. Results: The 129 treated patients (media..
View full abstractGrants
Awarded by National Cancer Institute Lymphoma Specialized Programs of Research Excellence Grant
Funding Acknowledgements
Research Funding: Anas Younes, Genentech, S*BIO, Novartis, Syndax Pharmaceuticals, sanofi-aventis; H. Miles Prince, Novartis; Simon J. Harrison, Novartis; Andreas Engert, NovartisSupported by Novartis Pharmaceuticals for clinical studies and medical editorial assistance and by National Cancer Institute Lymphoma Specialized Programs of Research Excellence Grant No. 1P50CA136411-01A1 to A.Y.